Tinea Pedis - Pipeline Insight, 2024

This Tinea Pedis - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 7+ pipeline drugs in Tinea Pedis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Tinea Pedis Understanding

Tinea Pedis: Overview

Tinea pedis or foot ringworm is an infection of the feet affecting soles, interdigital clefts of toes, and nails with a dermatophyte fungus. It is also called athlete’s foot. The infection is caused by the dermatophyte, Trichophyton rubrum which was once endemic to many parts of Africa, Asia, and Australia. However, today the organism can be found in Europe and the Americas. Occlusion of toe clefts, maceration, and wet conditions with a simultaneous increase in the bacterial flora probably contribute to tinea pedis infection. Skin breakdown, humidity, and temperature play a role in this infection. The fungus released enzymes called keratinases to invade the keratin layer of skin. In addition, the dermatophyte cell wall also contains molecules called mannans which suppress the body's immune response.

Tinea Pedis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tinea Pedis pipeline landscape is provided which includes the disease overview and Tinea Pedis treatment guidelines. The assessment part of the report embraces, in depth Tinea Pedis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinea Pedis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Tinea Pedis R&D. The therapies under development are focused on novel approaches to treat/improve Tinea Pedis.

This segment of the Tinea Pedis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Tinea Pedis Drugs
Dapaconazole: Biolab Sanus Farmaceutica Dapaconazole is a inhibitor of 14 alpha demethylase, being developed by Biolab Sanus Farmaceutica, for the treatment of tinea pedis and tineacruris.

Tinea Pedis: Therapeutic Assessment

This segment of the report provides insights about the Tinea Pedis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Tinea Pedis

There are approx. 5+ key companies which are developing the therapies for Tinea Pedis. The companies which have their Tinea Pedis drug candidates in the most advanced stage, i.e. Phase III include Biolab Sanus Farmaceutica.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Tinea Pedis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Tinea Pedis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Tinea Pedis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tinea Pedis drugs.

Tinea Pedis Report Insights

• Tinea Pedis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Tinea Pedis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Tinea Pedis drugs?
• How many Tinea Pedis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tinea Pedis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Tinea Pedis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Tinea Pedis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sanotize Research and Development
• DermBiont
• Taro Pharmaceuticals USA
• Blueberry Therapeutics
• Biolab Sanus Farmaceutica

Key Products

• Nitric oxide
• DBI 002
• TA 103
• Terbinafine hydrochloride
• DBI 001
• Dapaconazole